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Background: Diagnosis of acute coronary syndrome (ACS) is important, due to the associated
very high mortality. Failure to diagnose ACS is a problem both for the patients and the
clinicians. Ischemia modified albumin (IMA) has already been licensed by the US Food and
Drug Administration for the diagnosis of suspected myocardial ischemia.
Methods: Patients attending the emergency department (ED) within 6 h after having fea-
tures of ACS were selected. IMA was done on admission. Blinded to the IMA results patients
were fully evaluated and a diagnosis of non-ischemic chest pain (NICP), unstable angina
(UA) or myocardial infarction (MI) was made. Later IMA results were correlated in each
group.
Results: Mean IMA value was 56.38 ± 23.89 u/ml in NICP group whereas in UA group it was
89.00 ± 7.76 u/ml and MI group was 87.50 ± 9.62 u/ml. This showed a sensitivity of 92% and
specificity of 87%. The positive predictive value of the test was 88% and negative predictive
value was 94%. In 16 patients an early diagnosis could be made when compared with Trop-
T. Of the 89 patients 11 patients died in hospital. The IMA value was compared between
this group and the patients who survived. Patients who died had a mean IMA value of 88.5
with a standard deviation of 5.33 whereas in patients who survived the mean value was
78.26 which was not statistically significant.
Conclusion: In conclusion the benefit of the test would be to rule out ACS in patients who
present early to ED with inconclusive diagnosis.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
The acute coronary syndrome (ACS) represents a spectrum of
diseases which range from ‘Unstable Angina (UA)’ which is(C. Bhakthavatsala Redd
ciety of India. All rightsassociated with a reversible myocardial cell injury, to an ST-
segment elevation ‘Myocardial Infarction (MI)’ which is asso-
ciatedwith irreversiblemyocardial necrosis.1 In today's world,
about 17 million deaths occur due to cardiovascular disease.y).
reserved.
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heart disease increased from 1.17 million in 1990 to 1.59
million in 2000 and to 2.03 million by 2010.2 The diagnostic
approach and the clinical management of the patients who
present with a suspected acute coronary syndrome or cardiac
dysfunction are challenging3 (Fig. 1).
The manifestations of myocardial ischemia are varied and
multiple, like chest pain, epigastric discomfort, breathless-
ness, nausea and vomiting. However, these symptomsmay be
subtle and they may not be easily recognized. Because of their
varied presentations and as they are associated with high
mortality, an early identification of the patients with acute
myocardial infarction is very critical.4
Assessment of the cardiac biomarker levels (Myoglobin,
Creatine Kinase-MB and Troponins) is one of the most
essential and effectiveways for detectingmyocardial damage.
The current conventional cardiac markers, CK-MB, Troponin I
(TnI) and T are sensitive and specific tests for the detection of
myocardial necrosis, but they show a greater rise approxi-
mately 3e6 h after the onset of the myocardial cell injury and
other diagnostic tools such as stress testing, and echocardi-
ology are not routinely available.5
Recent research has found that ischemiamodified albumin
(IMA) is an ideal biomarker for ischemia. IMA is a form of
human serum albumin in which the N-terminal amino acids
have been modified by ischemia. This modification reduces
the affinity of plasma albumin to bind to heavy metal ions
such as cobalt.6 Bhagwan et al and others have shown
increased IMA levels in patients with spontaneous coronary
ischemia, with abnormal values which are detectable before
the subsequent increases in the cardiac troponin.7 Initially,
the test was named as the Albumin Cobalt Binding (ACB)
assay, since it was based on human serum albumin for the
metal ions (cobalt COII) in patients with ischemia.4
Failure to recognize ACS has unfavorable consequences
not only for patients, but for physicians too. Missed acute
cardiac ischemia continues to be one of the major causes of
malpractice litigation against emergency physicians. Twenty
percent of ED-related malpractice compensation is expended
to patients with complications because of myocardial
ischemia.8 The large number of patients presenting to EDs
with symptoms suggestive of ACS, and the medical and legal
consequences of an erroneous discharge from the ED, de-
mand that clinicians pursue new diagnostic approaches to
ACS.9Fig. 1 e Mean IMA values.Very few studies have been reported on the serum IMA
testing and on its application in the Indian context. This
proposed study aims to evaluate the added diagnostic value of
biomarker “Ischemia Modified Albumin (IMA)”, in patients
with ACS beyond other diagnostic tests to reliably detect
myocardial ischemia in the absence of necrosis, it's role in
differentiating UA versus MI, it's role in providing clinical
utility complementary to that of cardiac troponins, the
established markers of necrosis in NSTEMI & STEMI, role of
IMA in predicting in-hospital mortality.2. Materials and methods
The study was conducted after getting the approval from the
ethical committee of Narayana Medical College. Eighty nine
subjects were chosen for the study. Bothmales and females in
the age group of 20e75 years were included and an informed
consent was obtained from all of them. In this, 24 subjects
with symptoms of chest pain with normal, clinical,
biochemical and ECG parameters served as the control group.2.1. Patient selection
Data were collected from this 89 patients admitted to our
emergency department with manifestations suggestive of
acutemyocardial ischemia, including those such as chest pain
with or without radiation, chest heaviness, shortness of
breath, lower jaw pain, left arm pain, epigastric pain, syncope,
hypotension, palpitations, and other symptoms suggestive of
an anginal equivalent. Cardiac biomarker of necrosis-Trop-T
was measured and ECG taken in the ED within 30 min as
part of the standard care. All patients received routine insti-
tutional care blinded to the IMA results.2.2. Inclusion criteria
Patients admitted in the emergency room with a primary
complaint of chest pain or angina equivalence evolvingwithin
6 h and suspected as acute coronary syndrome.2.3. Exclusion criteria
1) Presence of renal diseases.
2) Presence of cirrhosis.
3) Presence of stroke, skeletal muscle injury, malignancy,
trauma.
4) Ongoing infectious diseases.
5) Serum albumin <2 g/dl.
6) Patient younger than 18 years old.
7) Patients with complaints lasting more than 6 h, as IMA
levels usually return to normal 8e12 h after onset of
myocardial ischemia.
8) Patients whose symptoms had ceased 2 h previously,
because IMA levels fall rapidly once an ischemic event has
ended.
9) Asymptomatic patients, and thosewho unable to relate the
time that their symptoms began or ended (if the pain was
not persisting).
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Demographics, clinical information, and hospital course
following enrollment were recorded for each patient. Data
analyzed included clinical history and examination, all rele-
vant electrocardiograms (ECGs), echocardiography, stress-
testing data, cardiac catheterization data, hospital course
documentation, and discharge summaries.
2.5. ECG classification
Positive ECGs were those with ST segment depression or
elevation [greater than or equal to] 0.1mV, or Twave inversion
[greater than or equal to] 0.2 mV (in [greater than or equal to]
two contiguous leads). ECGs showing no ST segment shifts or
T wave changes (apart from lead III or VI) were considered
negative. Equivocal or uninterruptable ECGs (that is, left
bundle branch block, paced rhythm, extensive pathological Q
waves, and/or persistent ST segment elevation after previous
AMI) were considered to be negative in this study.
Based on available data, a diagnosis of myocardial
ischemia was established or excluded for each patient. This
decisionwasmade in the light of objective and subjective data
relevant to the nature of the patient's manifestations,
including the results of history, physical examination, ECG,
cardiac biomarkers other than IMA, hospital course (including
results of diagnostic studies such as cardiac catheterization),
and discharge summaries.
Patients were classified as non-ischemic chest pain (NICP)
and acute coronary syndrome (ACS). ACS included unstable
angina (UA), non-ST segment elevation myocardial infarction
(NSTEMI), and ST segment elevation MI (STEMI). Practice
guidelines for the redefinition of AMI (ESC/ACC) and the
management of patients with UA (ACC/AHA), were used to
diagnose ACS.10,11 STEMI was diagnosed if there was ST
segment elevation [greater than or equal to] 0.1 mV in two or
more contiguous leads, and NSTEMI was diagnosed if ECGwas
non-diagnostic and cTnT positive. All patients underwent
serial cTnT testing at presentation and 6 h later as per insti-
tutional protocol for management of acute chest pain pa-
tients. UA was diagnosed in the presence of signs and
symptoms of acute cardiac ischemia without evidence of
myocardial necrosis. Positive indications for UA were a sug-
gestive history and clinical examination; typical ischemic ECG
changes at rest or during exercise; regional wall motion ab-
normality on echocardiography, significant stenosis (>70%) on
coronary angiography. Patients were classified as non-
ischemic chest pain (NICP) when (1) a reported non-cardiac
mechanism was confirmed as the cause of chest pain; (2) all
of the following criteria were met: atypical symptoms, nega-
tive cTnT results on serial sampling (over a 6e9 h interval),
presence of normal ECGs, and negative stress test.
2.6. Angiography and final diagnosis
Coronary angiography was carried out on all ACS patients. All
angiographic images were reviewed by an experienced
cardiologist blinded to the patient's IMA results. A positive
angiogram was defined as stenosis [greater than or equal to]
70% diameter reduction in any major epicardial vessel. Finaldiagnosis for this study was based on the history, clinical
examination, serial cTnT results, ECG, exercise stress testing
and coronary angiography, as available. Results of all in-
vestigations were reviewed blinded to IMA results.
2.7. Blood collection
5ml of blood samples were collected by venous puncture with
strict aseptic precaution as soon as the subjects got admitted
as per the inclusion criteria. The samples were centrifuged
and serum separated. One part of the sample was taken and
analysis of cTnT, albumin and serum creatinine were done
immediately. Remaining part of the sample was stored for
analysis of ischemia modified albumin at 20 C. cTnT was
repeated after 6 h if the first sample was negative.
2.8. Albumin cobalt binding test
IMA was measured by the albumin cobalt binding test (ACB
Test) on the Roche Cobas MIRA PLUS instrument. The mech-
anism whereby IMA represents a marker of ischemia is based
upon the fact that human serum albumin (HSA) has the ability
to bind certain transition metal ions, particularly cobalt and
copper, at the N-terminus. Bar-Or has previously reported that
exposure of albumin to ischemic tissue changes the structure
of HSA N-terminus such that it can no longer bind cobalt.12,13
Blood was collected for the IMA test in serum separated
tubes. Specimens were frozen at 20 C or colder within 2 h.
Frozen samples were gently vortexed after thawing. Speci-
mens handled in this way showed no significant difference in
assay results from the fresh specimens. In the ACB Test, 95 m
of a patient sample and 5 m of cobalt chloride (CoII), are
incubated for 5 min. During incubation, the Co(II) binds to the
N-terminus of unaltered albumin in the sample; albumin for
which the N-terminus is altered as a result of ischemic pro-
cesses binds to the Co(II) to a far lesser extent. After incuba-
tion, 25 m of dithiothreitol (DTT) is added to the mixture. DTT
forms a coloured complex with Co(II) that is not bound at the
N-terminus of albumin, and this complex is measured spec-
trophotometrically at 500 nm. Duplicate IMA values were ob-
tained with the mean recorded as the result of the assay.
In our laboratory, the ACB test within-run duplicate CV% of
patient samples averaged 1.9% (range 0.0%e6.5%). We applied
the IMA upper limit of normal (95th percentile of 111 appar-
ently healthy people) reported by the manufacturer. IMA
values >80 u/ml were considered positive for cardiac
ischemia.
2.9. Cardiac troponin T test
Bloodwas collected for the cTnT test in serum separated tubes
and cTnT concentrations >0.05 ng/ml were considered posi-
tive. cTnT concentrations were measured by electro-
chemiluminescence assay.
2.10. Statistical analysis
The statistical analysiswas executed bymeans of sigma graph
pad prism software, USA Version-4. Continuous data is pre-
sented as mean, median, range and standard deviation. With-
Table 1 e Patient clinical characteristics.
Clinical Parameter NICP UA MI
(n ¼ 24) (n ¼ 25) (n ¼ 40)
Age 49.5 ± 1.3 54.7 ± 12.1 52.7 ± 1.4
Gender 12/12 13/12 13/27
Time to hospitalization 3.17 ± 2.40 2.86 ± 2.00 3.78 ± 1.83
HTN 11 11 14
DM 11 15 17
Smoking 10 7 19
Mortality 0 3 8
Table 3 e IMA versus cTnT.
Biochemical parameters NICP UA MI
(n ¼ 24) (n ¼ 25) (n ¼ 40)
Elevated IMA 3 23 34
Positive Troponin-T at admission 0 0 18
Positive Troponin-T after 6 h 0 0 40
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between group analyses by unpaired “t” test. Categorical data
is presented as actual numbers and percentages. Categorical
variables were analyzed with “Fischer's exact test”. Pearson
correlations were used to determine the association between
variables. 2 by 2 tables were used to assess the diagnostic
value of IMA as positive and negative predictive values,
sensitivity and specificity was calculated with 95% confidence
interval.
2.11. Outcome measurements
The primary outcome analysis compared IMA values in pa-
tients diagnosed as ACS versus NICP. The use of IMA in early
diagnosis of MI when compared with Trop T was also
evaluated.3. Results
Our study included a total of 89 patients (51 men, 38 women,
median age 52.7 years). Sufficient data were available for all
the patients for a final diagnosis to confirm or exclude CAD.
The final diagnostic classification according to ESC/ACC
criteria was 24 non-ischemic chest pain (NICP) and 65 coro-
nary artery disease. Among the CAD patients, 26 had STEMI,
14 had NSTEMI, and 25 had UA.
Average duration of presentation was 3.27 h. Of the total of
89 patients 36 had history of hypertension and 43 had diabetes
mellitus.36 patients were smokers.11 patients expired while
in hospital (3 in UA group and 8 inMI group). Table 1 shows the
patient characteristics in each individual group.
3.1. IMA in ischemic versus non-ischemic chest pain
Median IMA values were significantly higher in patients with
ACS compared with NICP (p, 0.0001), in patients with UA
compared with NICP (p, 0.0001), and in patients with NICPTable 2 e IMA values.
NICP
(n ¼ 24)
IMA (Mean value) 56.38 ± 23.89 8
Elevated IMA (number of patients) 3 2compared with MI (p ¼ 0.001). But between UA and MI there
was no significant difference (Table 2).
The normal IMA value was taken as 80 u/ml. In the NICP
group mean IMA value was 56.38 ± 23.89 u/ml whereas in UA
group it was 89.00 ± 7.76 u/ml andMI groupwas 87.50 ± 9.62 u/
ml. IMA value was normal in 21 of 24 patients in NICP group
whereas it was elevated in 23 of 25 patients in UA group and 34
of 40 patients in MI group.
This showed a sensitivity of 92% and specificity of 87%. The
positive predictive value of the test was 88% and negative
predictive value was 94%.
3.2. UA versus MI
Although non-significant the IMA value was elevated more in
unstable angina than MI.
3.3. IMA in early diagnosis of MI
Comparing IMAwith Trop-T showed that IMAwas elevated in
34 of 40 patients at admission whereas Trop-T was positive in
only 18 of the 40 patients. So in 16 patients an early diagnosis
could be made when compared with Trop-T. IMA and Trop-T
values are given in Table 3.
3.4. IMA and peri-hospital mortality
Of the 89 patients 11 patients died in hospital. The IMA value
was compared between this group and the patients who sur-
vived. Patients who died had a mean IMA value of 88.5 with a
standard deviation of 5.33 whereas in patients who survived
the mean value was 78.26 which was not statistically signifi-
cant. Comparison values are given in Table 4.4. Discussion
The use of biomarkers for the identification of suspected acute
coronary syndromes depends on the presence of myonecrosis
as a surrogate indicator for myocardial ischemia. However,UA MI p value
(n ¼ 25) (n ¼ 40)
9.00 ± 7.76 87.50 ± 9.62 NICP vs UA, p ¼ 0.001
NICP vs MI ¼ 0.001
UA vs MI, p ¼ 1.00
3 34
Table 4 e IMA values and in-hospital mortality.
IMA values Died Alive
N 11 78
Minimum 81 14.2
Maximum 99 112.6
Mean 88.55 78.26
Std. Deviation 5.336 21.17
p value 0.1139
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myonecrosis, andmarkers such asmyoglobin, CK-MB, and the
troponins, although mainstays for the diagnosis of acute
cardiac myonecrosis, thus have limited role. Furthermore, the
release of these markers is time-dependent; an initially
negative result does not exclude the presence of MI. There-
fore, a rapidly detectable, highly sensitive marker for
myocardial ischemia would be desirable to identify patients
with only ischemia and those early in the course of an acute
coronary syndrome. For such a marker to be useful, it should
be accompanied by a high negative predictive value. This is
where the role of IMA comes in.4.1. IMA in ischemic versus non-ischemic chest pain
In this study we found that the use of IMA at presentation
could be used to both confirm and exclude a final diagnosis of
coronary artery disease. It is apparent from the data shown
above that for the emergency medicine physician, the role of
this test will be to exclude those likely to have CAD at pre-
sentation. A negative test allows exclusion of CAD.
In the study by Bhagwan et al,7 the sensitivity and speci-
ficity formyocardial ischemia were 88% and 94%, respectively,
and the positive and negative predictive values were 92% and
91%. The ACB test, however, was a poor discriminator be-
tween ischemic patients with and without MI. This compared
well with our study.
The specificity values were very low in some of the studies.
One study by Sinha et al14 evaluated IMA for diagnosis of
cardiac ischemia in patients attending the ED with symptoms
of ACS. In the whole patient group, sensitivity of IMA at pre-
sentation for an ischemic origin of chest pain was 82% (95% CI,
74e88%), specificity was 46% (34e57%), the negative predictive
value was 59%, and the positive predictive value was 72%
(prevalence, 63%). IMA, ECG, and cTnT combined identified
95% of patients whose chest pain was attributable to ischemic
heart disease.
Roy et al15 studied 131 patients presenting to the ED with
symptoms suggestive of ACS but with normal or non-
diagnostic ECGs. All patients arrived to the ED within 3 h of
the last episode of chest pain and had negative cTn results on
admission to the ED. Cardiologists, unaware of IMA results,
reviewed all the patients' notes and hospital test results (ECG
exercise stress testing, dobutamine stress echo and coronary
angiography) to establish a final diagnosis of ACS or non-
ischemic chest pain. Ischemia modified albumin values were
significantly higher in 64 patients with myocardial ischemia
compared with 67 patients with non-ischaemic cardiac pain
(98.3 ± 11 versus 85.5 ± 15, p < 0.0001). At the optimum cut-off
point of 93.5 u/ml, IMA had a sensitivity of 75% for thediagnosis of myocardial ischaemia. The combination of IMA
(measured at presentation to the ED) and serial cTnT (6e12 h)
increased sensitivity to 82.8%.
Lee et al16 studied 413 patients who had visited the ED for
symptoms suspicious of ACS. Sensitivity and specificity of
IMA for identifying ACSwere 93% and 35.6%, respectively, and
the negative and positive predictive values were 91.8% and
39.6%, respectively. The combination of myoglobin, CK-MB,
and troponin-T had a sensitivity of 80.2% and specificity 57%
for the diagnosis of ACS. When IMA was included in the car-
diac marker panel, sensitivity increased to 94.5% while spec-
ificity fell to 45.1%.
A multicenter study by Christenson et al,17 involving 224
patients who arrived at the ED within 3 h after onset of signs
and symptoms suggestive of ACS, examined the ability of the
ACB test to predict a positive or negative cTnI result within
6e24 h after presentation. All patients had a negative cTnI
result at presentation. Patients were considered troponin
positive if 1 or more cTnI values were above the upper refer-
ence limit within 6e24 h. At the optimum cutoff for the ACB
test, sensitivity and specificity were 70% and 80%, respec-
tively, with a negative predictive value of 96%. There were 6
false negatives and 131 true negatives. cTnI alone was used as
the outcome measure, and electrocardiogram (ECG) status at
presentation was not considered in the design of the study.
The positive predictive value is only 33%.
Ameta-analysis of more than 1800 patients concluded that
in a large ED cohort with suspectedmyocardial ischaemia, the
combination of ECG, troponin and IMA has 94.4% sensitivity
and 97.1% negative predictive value for the final diagnosis.18
A study conducted in India by Chawla et al4 found that IMA
demonstrated good discrimination between the ischemic and
the non-ischemic patients with an Odds Ratio of 16.9
(6.29e46.87) than CK-MB which showed an Odds Ratio of 2.07
(1.18e6.08). Sensitivity and specificity of IMA for the detection
of ACS was 78.0% and 82.7% compared to 58.0% and 60.0%,
respectively for the CK-MB assay.
However not all studies had a positive outcome. The PRIMA
study19 conducted in 399 patients in the emergency depart-
ment of John Radcliff Hospital UK between 2005 and 2006
concluded that the sensitivity of IMA was insufficiently high,
with a small number of false negatives undermining the
safety of the test. Frequent false positives produce a low
specificity that limits the practical value of the test. The
disadvantage of this study was that it compared IMA with
cTnT & UA was not a part of final diagnosis.
This was supported by other studies also. A study by Soren
et al20 concluded that Ischemia modified albumin did not, at
any time, provide superior sensitivity or specificity compared
with other biomarkers and did not find the data supportive of
IMA as a standard marker in the emergency department.
IMA, which appears to be an indicator of oxidative stress,
may not be specific for cardiac ischemia. Data about IMA
concentrations in non-cardiac ischemia are limited. Anec-
dotal evidence suggests that IMA increases in stroke, end-
stage renal disease, liver disease, and some neoplasms.21 In
a study evaluating the ACB test for forearm ischemia, in-
creases in endogenous lactate inhibited the test.22 This result
was recapitulated with exogenous lactate in vitro. Such a
result raises caution concerning the significance of a negative
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and/or renal failure, all of which are situations where
increased lactate may exist.
In a group of marathon runners, IMA did not increase
immediately after a marathon run, indicating that skeletal
muscle ischemia during exercise does not change IMA con-
centrations. However, there were significant increases 24e48 h
after the run, which were attributed to exercise-induced latent
gastrointestinal ischemia.23 This latent increase is an issue that
may potentially complicate use of the test in clinical practice.4.2. UA versus MI
When evaluating subsets of patients, we observed that IMA
values were higher, albeit non-significantly, in patients with
unstable angina compared to those with non-ST segment
elevationmyocardial infarction. A possible explanation for this
may be that the opportune window to diagnose ischemia prior
to the occurrence of myocardial damage in the patient sub-
group that progressed to myocardial necrosis was missed.
Previous studies have shown that IMA levels rise within mi-
nutes after ischemia and return to baseline within 6 h24 un-
fortunately,wedidnotcarryoutserial samplingmeasurements
that may have given additional information about marker ki-
netics and may have increased assay sensitivity for ACS.
The results indicate that IMA could be a potential marker
for early ruling out of ACS in chest pain patients because of its
relatively high NPV, especially combined with cTn and ECG.
Importantly IMA seems to add relevant diagnostic informa-
tion to more readily available diagnostic parameters. Howev-
er, problems with the stability of IMA and its lack of
cardiospecificity have been reported.
A negative test allows exclusion of CAD but a positive IMA
alone at presentation cannot differentiate betweenUA andMI.
This will need a follow up Troponin measurement to confirm
MI. There may be a number of reasons for this.
Firstly, IMA is a test for ischemia not infarction. Myocardial
ischemia may occur without proceeding to infarction. Previ-
ous studies of the ability of IMA to predict a positive cTn have
shown good performance with an area under the receiver
operator characteristic (ROC) curve of 0.78 but did not show
100% concordance in patients admitted with chest pain.17
Secondly, the study used as diagnostic “gold standard”with
elevatedcTnaccordingtoESC/ACCcriteria, is foracuteMIrather
than myocardial ischemia. There is currently no method of
reliably detectingmyocardial ischemia. Previous studies of IMA
have shown it is possible to distinguish reliably between the
ACS and non-ACS populations (area under the ROC curve 0.95)
but there is overlap when attempting to distinguish between
AMI and unstable angina7 (area under the ROC curve 0.66).4.3. IMA and peri-hospital mortality
Regarding the immediate prognosis our study could not find
any significant correlation between IMA values and expired
patients. A study conducted by Andrew Worster et al25 in 189
patients monitored patients who presented within 6 h of
angina for 72 h for any serious cardiac outcome. When they
correlated the IMA values there was no significant relation.The long term outcome of IMA value was not considered in
this study. The study which has monitored the long term
correlation of IMA was the French nationwide OPERA study26
which found that the primary composite end point (death,
resuscitated cardiac arrest, recurrent myocardial infarction or
ischemia, heart failure, stroke) occurred in 75 (15.6%) patients
in-hospital and in 144 (30.6%) at 1 year: 40% of patients in the
highest IMA quartile (>104 IU/mL) reached the end point
compared with 20% in the lowest (<83 IU/mL) by 1 year. They
identified IMA as one of the 4 independent predictors of
composite end point at 1 year the others being: plasma con-
centrations of brain natriuretic peptide (p ¼ 0.001), heart fail-
ure (p ¼ 0.005), and age (p ¼ 0.003).
The results of our study support the evidence that IMA is
an early marker of ischemia, increases before any detectable
change in cardiac troponin occur, is elevated even in the
absence of myocardial necrosis and is clinically useful in the
ED setting.
4.4. Limitation
Our study was conducted in a single center, which may limit
the generalizability of our results. Furthermore, our results
may not be applicable to all patients suffering from acute
chest pain, as we excluded patients with conditions known to
increase IMA levels, and also limited our observations to pa-
tients with chest pain within 6 h prior to the ED admission;
thus, the prognostic value of IMA in amore general population
has yet to be determined. Finally, the relatively small number
of patients included in the study dictates caution in the
interpretation of the results.
IMA values are altered in the following settings:
(i) IMA may increase in patients with stroke, end-stage
renal disease, liver disease, and some neoplasms. (ii)
Increased endogenous lactate levels appear to reduce IMA
concentrations, which raise concern about the true signifi-
cance of a negative IMA result in patients with sepsis or renal
failure where lactate may be present in the circulation. (iii)
IMA levels raise after radiofrequency catheter ablation and
direct current cardioversion, which could be due to the gen-
eration of reactive oxygen species following electrical and
thermal myocardial injury.
A further limitation is that the ACB test (the test currently
used tomeasure IMA) is a colorimetric assay, and therefore an
indirect measurement of IMA production. New assay plat-
forms (i.e. immunoassays), however, are expected to be
available in the near future.
We did not do a serial assay of the IMAhence the kinetics of
IMA in ischemia is not fully known. Further a long term follow
up was also not done.5. Conclusion
In our patients, IMA was useful to distinguish those with ACS
fromNICP subjects and in early diagnosis ofMI in patientswho
present early. This biomarkermay therefore constitute a useful
adjunct to our current diagnostic armamentarium in the ED
setting. However IMA could not differentiate between MI and
UA. Neither was it useful in predicting in-hospital mortality.
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albumin concentration changes need to be more fully under-
stood. Additional information is needed for the clinical vali-
dation of this new assay including studies on reference
distributions by gender and ethnicity; an optimum diagnostic
cutoff value for ACS patients, comparing IMA concentrations
in common disease states with or without accompanying
cardiac disease; and common diseases that coexist with car-
diac ischemia, such as congestive heart failure, diabetes
mellitus, chronic renal failure, and hypertension. A better
understanding of IMA kinetics over the early hours after the
onset of an ACS is also essential.
In summary, many questions remain unanswered
regarding IMA and the ACB test. The assay needs to be eval-
uated by incorporating it into decision-making algorithms
under ED conditions. The highest expected benefit of the test
would be to rule out ACS in patients with negative necrosis
markers and a negative ECG. This was the language for which
the ACB test was cleared by the FDA for clinical use.Conflicts of interest
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